Medtide Inc. (03880.HK)

Medtide, Inc. is a peptide focused contract research, development and manufacturing organization. The company is headquartered in Hangzhou, Zhejiang and currently employs 520 full-time employees. The company went IPO on 2025-06-30. The firm mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The firm's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The firm also provides customers with peptide drug development, production, and CMC filing support services. The firm mainly operates its business in the domestic market and overseas markets.